Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis

Study Type:Therapy

OE Level Evidence:1

Journal Level of Evidence:N/A

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

N Engl J Med. 2016 Oct 20;375(16):1532-1543

Contributing Authors: S Ferrari C Libanati JD Adachi E Czerwinski EM Lewiecki A Grauer F Cosman L Chen N Binkley E Lau DB Crittenden J Maddox CA Zerbini LC Hofbauer A Miyauchi CE Milmont PD Meisner

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

7180 postmenopausal women with osteoporosis were randomized to 12 months of treatment with either romosozumab or placebo, followed by a further 12 months of treatment with denosumab in both groups. The purpose of this study was to evaluate and compare vertebral fracture incidence, nonovertebral fracture incidence, and safety outcomes between groups after 6, 12, 18, and 24 months. Results after 12 ...